Heart failure & cardiomyopathies
Impact of Statin Therapy in Heart Failure Patients: Results of a Large Real-World Experience
Main findingResult — go to the resultAdjusted hazard ratio 0.53 95% CI 0.51–0.56Authors' conclusion
These results suggest a potential benefit of selective statin use in the real-world management of HFrEF patients with ASCVD or at high ASCVD risk.
Study context
- Population
- Patients with heart failure (HF) and EF ≤40% (HF with reduced ejection fraction (HFrEF)), Intermountain Healthcare medical records9,641 [64%] on statins
- Participants
- 15,010 patients
- Exposure
- Statin vs no statin
- Statinn = 9,641
- Outcome
- MACE:
- Death
- MI
- Stroke
- Follow-up
- Median 4.5 years
Methodological detailsCox proportional hazards regression
- Cox proportional hazards regression
Main finding
As reported in the abstract
Adjusted hazard ratio
0.53
95% CI 0.51–0.56
P < 0.0001
Statinvs No statin
adjusted HR 0.53 (95% CI 0.51–0.56); P < 0.0001
Observational data: associations, not effects.
Further findings
Major adverse cardiovascular events (MACE) by primary vs secondary prevention and prior vs new statin prescription
- Benefit similar for primary and secondary prevention and for prior and new statin prescriptions
MACE by duration on statin (time-varying HR analysis)
- Longer time on statin, greater reduction in MACE risk
- P < 0.0001
Original publication
Impact of Statin Therapy in Heart Failure Patients: Results of a Large Real-World Experience. JACC Adv. Published 30 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →